Pfizer Arthritis Medication Study
The Pfizer Arthritis Medication Study by Arizona Pain Specialists is part of a large clinical trial comparing three arthritis medications: celecoxib (Celebrex®), naproxen (e.g., Aleve®), and ibuprofen (e.g., Advil ®). Patients suffering from osteoarthritis or rheumatoid arthritis who are also at high risk of heart disease will take one of these medications for four years as heart and digestive problems are recorded.
COX-II selective inhibitors, such as celecoxib (Celebrex®), are an alternative type of medication developed for treating arthritis pain. Unlike other non-selective inhibitors, such as naproxen (e.g., Aleve®) and ibuprofen (e.g., Advil ®), celecoxib (Celebrex®) blocks only a specific enzyme that causes arthritis pain. Because they leave other enzymes unaffected, COX-II selective inhibitors can be easier on the digestive system. However, little is known about the safety of various arthritis medications for heart safety. This clinical trial is a large-scale study intended to provide the most complete information to date on the relative heart safety of these different arthritis medications.
Individuals who qualify for this study will be randomly assigned to receive one of three widely-used arthritis medications celecoxib (Celebrex®), naproxen (e.g., Aleve®), or ibuprofen (e.g., Advil ®) for four years as their heart and digestive health is monitored in periodic clinic visits.